Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC):: CALGB 80203 preliminary results.

被引：0
|
作者：
Venook, A.
Niedzwiecki, D.
Hollis, D.
Sutherland, S.
Goldberg, R.
Alberts, S.
Benson, A.
Wade, J.
Schilsky, R.
Mayer, R.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] CALGB Stat Ctr, Durham, NC USA
[3] Univ N Carolina, Chapel Hill, NC USA
[4] Mayo Clin, Rochester, MN USA
[5] Northwestern Univ, Chicago, IL 60611 USA
[6] Cent Illinois CCOP, Decatur, IL USA
[7] Univ Chicago, Chicago, IL 60637 USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3509
引用
收藏
页码：148S / 148S
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
    Aballea, S.
    Najib, M.
    Cure, S.
    O'Neil, B.
    ANNALS OF ONCOLOGY, 2006, 17 : 66 - 66
  • [2] The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (GONO).
    Falcone, A.
    Masi, G.
    Brunetti, I.
    Benedetti, G.
    Bertetto, O.
    Picone, V.
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Ricci, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 149S - 149S
  • [3] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] FLUOROURACIL/LEUCOVORIN (5FU/LV) COMBINED WITH IRINOTECAN AND OXALIPLATIN (FOLFIRINOX) AS SECOND LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayyar, C.
    Paul, M.
    Culine, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
  • [5] Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir)+5FU/LV (IrFL) followed by docetaxel (T)+5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)
    Loupakis, F.
    Masi, G.
    Bursi, S.
    Picone, V.
    Mentuccia, L.
    Granetto, C.
    Fea, E.
    Murr, R.
    Antonuzzo, A.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
    Kalofonos, H. P.
    Papakostas, P.
    Aravantinos, G.
    Papadimitriou, C.
    Pentheroudakis, G.
    Varthalitis, I.
    Tsavdaridis, D.
    Syrigos, K.
    Kosmidis, P.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [7] CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
    Venook, Alan P.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Innocenti, Federico
    Mahoney, Michelle R.
    O'Neil, Bert H.
    Shaw, James Edward
    Polite, Blase N.
    Hochster, Howard S.
    Atkins, James Norman
    Goldberg, Richard M.
    Mayer, Robert J.
    Schilsky, Richard L.
    Bertagnolli, Monica M.
    David, Charles
    Blanke, Charles David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (18)
  • [8] CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (RV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
    Venook, Alan P.
    Niedzwiecki, Donna
    Lenz, Heinz-Josef
    Innocenti, Federico
    Mahoney, Michelle R.
    O'Neil, Bert H.
    Shaw, James Edward
    Polite, Blase N.
    Hochster, Howard S.
    Atkins, James Norman
    Goldberg, Richard M.
    Mayer, Robert J.
    Schilsky, Richard L.
    Bertagnolli, Monica M.
    Blanke, Charles David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) IN METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS OF A PHASE II GONO TRIAL
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Di Marsico, Roberta
    Antonuzzo, Andrea
    Baldi, Giacomo Giulio
    Stasi, Irene
    Pfanner, Elisabetta
    Ciarlo, Andrea
    Del Monte, Francesca
    Conte, Davide
    Iacovelli, Roberto
    Sonaglio, Claudia
    Granetto, Cristina
    Donati, Sara
    Andreuccetti, Michele
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2009, 20
  • [10] Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial
    Masi, G.
    Salvatore, L.
    Fornaro, L.
    Vasile, E.
    Baldi, G. G.
    Stasi, I.
    Ciarlo, A.
    Tuzi, A.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
12345